Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| We're executing at full speed our previously announced company-wide value creation initiatives extended to the right size of our business to current levels of market demand and deliver value to our shareholders and in 2023 in a much stronger operational and financial position |
| That will be significant, for the -- for [reassuring] (ph) the second half of the year has been excellent, at least in the last quarter |
| We have a very strong portfolio of orders for the last quarter of the year |
| [Time] (ph) was positively impacted by the higher demand and the rollout of new products in the region and the increased market share of existing brands |
| Exchange rates are now starting to help in the first part of the third quarter, bolstering our recovery for the rest of the year and was positively impacted by the rollout of new products and portfolio expansion in several therapeutic areas such as gastrointestinal and feminine care and strong performance in Nicaragua and Honduras, but this positive impact was offset by the OTC segment in El Salvador |
| In our path to full recovery, we believe third quarters will have a better performance than second quarter of 2023, very much in line with last year's third quarter, and we strongly believe that the fourth quarter 2023 would be a very strong quarter |
| Despite these hurdles, we are optimistic our ability to deliver growth in the medium to long term |
| We feel very confident in the Board that the agility and the way we're facing the future of the company, it's a -- it is in very good terms |
| And CASAND region, we have found excellent growth of approximately 26% in the first quarter of 2023 with the new important launches for the second half of the year |
| We believe our growth plan, including these new product launches and rollouts, combined with our value creation initiatives will result in strong demand of our aggressive plan to reduce expenses and generate efficiencies will position us for continued growth |
| It's in very good shape |
| And we are getting great results along the way |
| The top-line growth was broad based across several therapeutic areas with increased demand for both our Rx and Clinical Specialties products which grew 15% and 16% respectively in first half ’23 versus first half ‘23 |
| We continue working on the execution of our value creation initiatives with price increases, contract adjustments, improvement of our product mix with new launches and containing costs |
| Our renewal rate that is a percentage of our revenues coming from products launched in the last 36 months was a record of 34% in the first half |
| Ramp up for products launched in the last 36 months is performing quite well, highlighted several products, such as Aludel, which is an oncological prostate cancer product and Dolofen Xtra, which is the first ever Unigel triple combo for migraines |
| So -- but I would say the most important benefit for us is that we were able to extend it |
| This, as we mentioned, the third quarter will be good, but not significantly higher than last year’s, but the fourth quarter is definitely going to make a very big difference with what we had last year |
| I would say given the setback that we had in the last part of last year, and that we're recovering and we have a tight cash, I think the focus for this year is definitely executing the efficiency plans, the value creation initiatives, getting back to our cash position, improving our EBITDA so that we can regain our debt or leverage capacity |
| In addition, we had the recognition of sales of brands in the second quarter of 2022 which positively impacted gross profit for the prior period |
| Very good |
| When we look at the growth per business lines, we have Rx growing approximately 15% in the first half of the year, outgrowing the market by a quite a good percentage, especially in countries like Colombia, Ecuador, Honduras, Dominican Republic and Panama |
| I will ask you to keep in mind that number one, we are conscious, very conscious of the temporary hurdles, and we are working on them, all of them, or most importantly, the fundamentals and the demand for recreational products are as strong as ever |
| For the time being, as we're not blind to the challenges, we will continue to work in a disciplined and creative way to improve our results quarter-over-quarter |
| So we are optimistic that we'll get there |
| Clinical Specialties grew approximately 6% in the same period on a constant-currency basis |
| Our new product launches have been a key driver for our growth |
| We're continuing to work on our value creation and market growth initiatives and speeding up our plans to make the company better in the medium and long term |
| Unigel, for example, that Ruben just mentioned, besides plastic demands reduction, deploys different environment benefits across the whole supply chain |
| And this is just one example where we can see our own patented technologies playing an important role in and delivering a differentiated product to the marketplace |
| Statement |
|---|
| The pressure that some of our customers have had to reduce their working capital, both abroad and the US are also due to the economic conditions in Colombia have made it harder to sell the full amount that we had anticipated |
| As just mentioned, the [Nextgel] (ph) business segment has been negatively impacted by challenges that also affected our partners, resulting in lower inventory levels on their side, delaying orders on our side |
| Our adjusted EBITDA has negatively impacted by the effects we have seen in gross margin and higher comparison base in the second quarter 2022 |
| I -- we have, as we mentioned, the CDMO business had some delays in orders because of the working capital policies of some of our large pharma customers |
| The toughest issue we have had to deal with this year are the macroeconomic, environmental and challenge -- that challenge the entire industry in our region |
| Although the Colombian peso has had an important appreciation since April, currency has still been a negative for us in the second quarter compared to last year |
| So that has put pressure on our efforts to improve our working capital |
| Both in the quarter and in the first half ‘23, we saw higher costs, a less favorable sales mix and lower sales of high margin product development services |
| The continued cash pressures for some of our CDMO clients could pressure them into further the tightening of the working capital, therefore reducing their purchase order for the second half |
| While we faced a tough first half of the year, and it is true that we did not do as well as we hoped, the measures that we have started implementing late last year are already bearing the results of our full recovery |
| When we look at the guidance for the year, we see some risks that we're working to mitigate |
| Unfortunately, this kind of Board turnover doesn't cast things in a good light |
| So excluding this impact, on a constant currency basis, we ended with an increase of 4.3% in revenues for second quarter ‘23 and 7% for first half ‘23, which was negatively impacted by CDMO order phasing, especially for US clients, decrease of sales related to Rymco ceased operations and a decrease of sales in the OTC market in El Salvador |
| We have made advancements, but there have been delays, as we mentioned in the press release and in now in the speech |
| The political macro environment in Colombia could affect our business if the economic conditions deteriorate or if there are changes in the health care regulation |
| It's just it's taking us longer than we that we anticipated |
| Colombia was impacted by overall macro conditions in the country that have translated in customers reducing their purchase orders to improve their working capital |
| We are affected by multiple factors such as rising costs and expenses from inflation, high interest rates, and cost of financing, reduced orders from pharma companies in our CDMO business due to working capital concerns |
| Moving to Slide 7, I would like to give a bit more color on our gross profit, which was down from last year |
| The cash balance for the first half of the year has decreased mainly due to the low results we had in the fourth quarter 2022, which traditionally is the strongest quarter in the year and the one that provides the cash to endure the lowest months of the year |
Please consider a small donation if you think this website provides you with relevant information